Binding agents binding to PD-L1 and CD137 and use thereof
US-12570751-B2 · Mar 10, 2026 · US
This page is not indexed by search engines while we improve data quality.
Rademaker Rik patents
Rademaker Rik is listed as an inventor on 72 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Rademaker Rik |
| Total patents | 72 |
| First publication | Nov 17, 2016 |
| Latest publication | Mar 10, 2026 |
Notable patents
Publications ranked by popularity score, then publication date.
Antibodies
US-2025340647-A1 · Nov 6, 2025 · US
Antibodies
US-2024392032-A1 · Nov 28, 2024 · US
Antibodies against pd-l1
US-2024317861-A1 · Sep 26, 2024 · US
Multispecific antibodies against CD40 and CD137
US-12077596-B2 · Sep 3, 2024 · US
Antibodies
US-11970544-B2 · Apr 30, 2024 · US
Multispecific antibodies against CD40 and CD137
US-11939388-B2 · Mar 26, 2024 · US
Humanized or chimeric cd3 antibodies
US-2023374131-A1 · Nov 23, 2023 · US
Agents, Uses and Methods for the Treatment of Synucleinopathy
US-2023312693-A1 · Oct 5, 2023 · US
Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer
US-2023257479-A1 · Aug 17, 2023 · US
Recent patents
Latest publications not already listed above.
Humanized or chimeric CD3 antibodies
US-11613575-B2 · Mar 28, 2023 · US
Multispecific antibodies against cd40 and cd137
US-2023089969-A1 · Mar 23, 2023 · US
Binding agents binding to pd-l1 and cd137 and use thereof
US-2023087745-A1 · Mar 23, 2023 · US
Humanized or chimeric cd3 antibodies
US-2023027394-A1 · Jan 26, 2023 · US
Agents, uses and methods for the treatment of synucleinopathy
US-11542323-B2 · Jan 3, 2023 · US
Agents, uses and methods for the treatment of synucleinopathy
US-11524995-B2 · Dec 13, 2022 · US
Humanized or chimeric cd3 antibodies
US-2022389101-A1 · Dec 8, 2022 · US
Humanized or chimeric cd3 antibodies
US-2022380464-A1 · Dec 1, 2022 · US
Antibodies
US-2022324980-A1 · Oct 13, 2022 · US
Binding agents binding to PD-L1 and CD137 and use thereof
US-11459395-B2 · Oct 4, 2022 · US
Multispecific antibodies against CD40 and CD137
US-11440966-B2 · Sep 13, 2022 · US
Agents, uses and methods for the treatment of synucleinopathy
US-11421024-B2 · Aug 23, 2022 · US
Humanized or chimeric CD3 antibodies
US-11359015-B2 · Jun 14, 2022 · US
Multispecific antibodies against cd40 and cd137
US-2022064317-A1 · Mar 3, 2022 · US
Antibodies
US-11261254-B1 · Mar 1, 2022 · US
Antibodies
US-2022048999-A1 · Feb 17, 2022 · US
Antibodies
US-2022049013-A1 · Feb 17, 2022 · US
Multispecific antibodies against cd40 and cd137
US-2022033510-A1 · Feb 3, 2022 · US
Antibody formulation
US-2021369842-A1 · Dec 2, 2021 · US
Multispecific antibodies against cd40 and cd137
US-2021317225-A1 · Oct 14, 2021 · US
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Genmab As | 49 |
| H Lundbeck As | 23 |
| BioNTech SE | 19 |
| Biontech Ag | 1 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| C07K2317/565 | 72 |
| A61K2039/505 | 72 |
| C07K2317/92 | 72 |
| C07K2317/33 | 53 |
| C07K2317/21 | 53 |